Novavax (NVAX) submitted an application to the FDA, seeking to amend its Emergency Use Authorization (EUA) and update its protein-based COVID-19 vaccine for the upcoming fall season. While this updated vaccine has been formulated to target the JN.1 variant, management claims that the vaccine has also been shown to be effective against the current circulating strains, including KP.2 and KP.3. Subject to necessary permissions from the FDA and CDC, Novavax intends to market this updated COVID-19 vaccine in pre ...